Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sanjeev Balu
Expanded Access to Cancer Treatments From Conversion to Neutropenia Prophylaxis With Biosimilar Filgrastim-SNDZ
Future Oncology
Medicine
Cancer Research
Oncology
Related publications
Expanded Access to Pembrolizumab From Cost-Savings Generated by Biosimilar Filgrastim (BIOSIM-FIL) in the Prophylaxis of Chemotherapy-Induced (FEBRILE) Neutropenia (CIN/FN): Simulation Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn32 - The Effectiveness and Safety of Switching From Orginal Filgrastim to Biosimilar Filgrastim in Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia: A Retrospective Cohort Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Filgrastim-SNDZ Debuts as the First Biosimilar Approved in United States
Journal of Community and Supportive Oncology
Oncology
Hematology
Pharmacokinetic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial
Annals of Hematology
Medicine
Hematology
Filgrastim Therapy in a Child With Neutropenia Induced by Linezolid
International Journal of Clinical Pharmacy
Toxicology
Pharmacy
Pharmacology
Pharmaceutical Science
Quality Comparison of Biosimilar and Copy Filgrastim Products With the Innovator Product
Pharmaceutical Research
Organic Chemistry
Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
Comparison of the Pharmacodynamic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial
Annals of Hematology
Medicine
Hematology
FDA Approves First Biosimilar to Treat Cancer
Cancer Discovery
Oncology
Obstacles to Affordable Cancer Treatments
North Carolina Medical Journal
Medicine
